Toolkit · Agriculture

The Hemp License, Cannabinoid Testing, and Product Compliance Toolkit

19 U.S.C. § 1595

Type
Toolkit
Jurisdiction
National
Date
2025-10-18
Topic
Agriculture

This toolkit supplies the documents a hemp or cannabinoid business actually needs. It opens with the transport packet and driver instruction sheet that resolve a roadside seizure, and a certificate of analysis review protocol that separates evidence from marketing. It provides contract language for hot-lot allocation, conversion disclosure, and a definitional change clause that anticipates the law being rewritten mid-term. It includes an out-of-specification policy, laboratory engagement terms, a fifty-state matrix template, and a claims audit script that finds the disease claims a company does not know it made. It closes with a recall notification, a diligence request list for investors and acquirers, an insurance coverage questionnaire, and the intake questions that establish posture in one conversation.

The Hemp License, Cannabinoid Testing, and Product Compliance Toolkit

Agriculture > Hemp, CBD, and Intoxicating Cannabinoids | Published 18 October 2025 - Updated 30 May 2026 | UpLaw - uplaw.us

Tool 1 — Transport packet and driver instruction sheet

Field tests detect THC without quantifying it and cannot distinguish hemp from marijuana. The packet is what resolves the stop.

In the cab, physically, every load:

☐ Producer license (copy) ☐ Land or lot report for the lot in the trailer ☐ ☐ Certificate of analysis with sampling date, testing date, method, and analytes ☐ ☐ Bill of lading ☐ Manifest tying the load to the tested lot ☐ ☐ Statement of the federal transport protection ☐ Counsel's name and twenty-four-hour number ☐

Driver instruction sheet

This load contains hemp lawfully produced under license [number] and tested at [laboratory] on [date]. The certificate of analysis is in this packet.

If stopped and asked about the cargo: state that it is licensed hemp, hand over this packet, and call the number below. Do not consent to a search beyond what is required. Do not speculate about THC content, about how the product is used, or about the law. Do not sign any document characterizing the cargo.

If the load is seized: ask for a receipt identifying the quantity seized, the agency, the case number, and the officer. Ask that the material be preserved and stored in conditions that will not degrade it. Photograph the load and the seal before it leaves your custody. Call counsel immediately — this cargo is perishable and an interim release motion is time-sensitive.

Counsel: [name], [phone], available at any hour.

☐ ⚠️ A state may not bar transportation through it. A state may bar production and sale within it. The cargo is protected in transit and unlawful if it stops. ☐ Destination state checked this quarter ☐ Carrier's own policies checked ☐ ☐ Import or export analysis where applicable — 21 C.F.R. Part 1312; 19 U.S.C. § 1595 ☐

Tool 2 — Certificate of analysis review protocol

Never accept a certificate as a conclusion. Run this every time.

Check Requirement Pass
Subject Finished product, not the input ☐
Lot code Matches the code on the package physically ☐
Laboratory Named, accredited, scope covers this matrix ☐
Method Stated; liquid vs. gas chromatography identified ☐
Analyte Delta-9 alone or total THC; conversion factor shown ☐
Chromatogram Obtained, not just the summary page ☐
Sampling record Plant part, compositing, sampler identity ☐
Uncertainty Stated, with the program's treatment applied ☐
Panel Full cannabinoid panel, not a single number ☐
Contaminants Residual solvents, heavy metals, pesticides, microbials ☐
Dates Analysis date within a defensible interval of shipment ☐

☐ ⚠️ Without method, chromatogram, sampling record, and uncertainty, a certificate is a marketing document. ☐ Governing measurement identified for this material at this stage: total THC (cultivation) ☐ delta-9 concentration (product definition) ☐ 21 U.S.C. § 802; 7 C.F.R. Part 990 ☐

Tool 3 — Hot lot allocation clause

Testing, rejection, and loss allocation

(a) Governing measurement. Compliance shall be determined by [total THC computed as delta-9 THC plus 0.877 times THCA / delta-9 THC as measured], reported by a laboratory accredited to [standard] using [method].

(b) Sampling. Samples shall be taken by [party] in accordance with [protocol], from [plant part / finished lot], with the sampling record delivered with the result.

(c) Measurement of uncertainty. A reported value shall be deemed compliant if the acceptable level falls within the reported measurement of uncertainty.

(d) Retest. Either party may require one retest at [laboratory], on the retained sample, within [days]. The cost is borne by [the requesting party / the party whose position is not sustained].

(e) Remediation. Before rejection, Seller may remediate by [flower removal / whole-plant blending] and resubmit for testing within [days].

(f) Rejection and loss. If the lot remains non-compliant, [allocation: Seller bears the loss / the parties share as follows / Buyer's deposit is refunded and no further liability attaches]. Neither party shall dispose of non-compliant material except in accordance with the governing program, with documentation delivered to the other.

(g) Notice. Each party shall notify the other within [hours] of receiving any result at or near the threshold.

☐ ⚠️ Silence on this clause is the most expensive silence in the industry.

Tool 4 — Conversion disclosure and representation

Cannabinoid origin representation

Seller represents and warrants that each cannabinoid in the Product [was extracted directly from hemp without chemical conversion / was produced by conversion of a hemp-derived precursor, specifically: [describe process, reagents, and starting material]].

Seller shall maintain batch records disclosing any conversion and shall produce them to Buyer on request. Seller indemnifies Buyer against any claim, seizure, forfeiture, or enforcement action arising from the characterization of any cannabinoid in the Product as a synthetically derived tetrahydrocannabinol or a controlled substance analogue.

☐ Exposure framework understood — 21 C.F.R. Part 1308; 21 U.S.C. § 813 ☐ ☐ Textual defense preserved: the definition covers derivatives, extracts, cannabinoids, and isomers ☐ ☐ Deference posture — Loper Bright Enterprises v. Raimondo ☐ No equitable exception for a controlled substance — United States v. Oakland Cannabis Buyers' Cooperative ☐ ☐ ⚠️ A batch record that conceals a conversion is far worse than one that discloses it.

Tool 5 — Definitional change clause

Change in law

"Change in Law" means any amendment to the federal definition of hemp, any imposition of a limit on total THC or on milligrams per serving or per container, any scheduling of a cannabinoid contained in the Product, or any state enactment prohibiting the Product in a Territory.

On a Change in Law: (i) the affected party shall give notice within [days]; (ii) obligations to manufacture or ship into the affected jurisdiction are suspended; (iii) Buyer may return unsold affected inventory for credit at [price], or the parties shall share the loss [allocation]; (iv) either party may terminate as to the affected Products on [days] notice without liability other than for goods delivered; and (v) neither party shall be liable for consequential damages arising from a Change in Law.

The parties acknowledge that the legal status of the Product depends on statutory definitions subject to amendment, and that this clause allocates that risk in lieu of any doctrine of impracticability or frustration of purpose.

☐ ⚠️ Absent this clause the parties litigate impracticability with unpredictable results. ☐ State authority preserved by 21 U.S.C. § 903 ☐ Constitutional limits — National Pork Producers Council v. Ross; Tennessee Wine and Spirits Retailers Association v. Thomas ☐

Tool 6 — Out-of-specification policy

Adopt before you need it. Every version of a result is discoverable.

☐ Trigger. Any result outside specification, including one within measurement uncertainty of the limit. ☐ Immediate quarantine of the lot. No release pending investigation. ☐ Investigation with a written record: sampling review, laboratory review, method review, and a documented conclusion whether the result is attributable to an assignable cause. ☐ Retest permitted only where an assignable laboratory or sampling error is identified, on the retained sample, with the original result retained in the file. ☐ ⚠️ Retesting until a passing number appears, with failing results discarded, is the single most damaging fact pattern in this industry's litigation. ☐ Disposition recorded: release, remediate, or destroy, with the basis. ☐ Notification to buyers of affected lots where product has shipped. ☐ Trend review quarterly across all out-of-specification events. ☐ Records retained for the longer of the program period or the applicable limitations period ☐

Tool 7 — Laboratory engagement terms

☐ Accreditation to a recognized standard, with the scope of accreditation attached ☐ ☐ Proficiency testing participation, with results provided annually ☐ ☐ Method validation documentation on file ☐ ☐ Turnaround commitment and escalation path ☐ ☐ Analytes and reporting format specified, including measurement of uncertainty ☐ ☐ Sample retention period — long enough to permit a retest when a dispute surfaces months later ☐ ☐ Chromatograms provided with every report or on request without charge ☐ ☐ Agreement that an analyst will testify if required, and the rate for doing so ☐ ☐ Confidentiality, and a conflicts disclosure where the laboratory serves both sides of a supply relationship ☐ ☐ Manufacturing context for the samples submitted — 21 C.F.R. Part 117; 21 C.F.R. Part 111; electronic records under 21 C.F.R. Part 11 ☐

Tool 8 — Fifty-state matrix template

State Lawful? THC measure mg cap serving mg cap container Age Packaging Testing / COA License or registration DTC shipping Effective date Checked

☐ Pattern coded for each state: prohibition ☐ caps ☐ channeling into cannabis licensure ☐ light-touch ☐ minimal ☐ ☐ Matrix dated ☐ Reviewed quarterly ☐ Owner named ☐ ☐ ⚠️ Never ship into a state not checked this quarter. ☐ Constitutional overlay noted — Gonzales v. Raich; Wickard v. Filburn ☐

Tool 9 — Claims audit script

Most disease-claim enforcement traces to material the company did not write. Run this annually and before any transaction.

☐ Package and insert. Every SKU, every version currently in the field, photographed. ☐ Website. Every page, including landing pages, blog posts, FAQ entries, and pages no longer linked but still live. ☐ Archived pages. Search a web archive for prior versions. ⚠️ Claims removed three years ago are discoverable and actionable. ☐ Social media. Every account, every platform, including accounts run by regional distributors. ☐ Influencers and affiliates. Every post under a paid relationship. Obtain the list from marketing and from accounts payable — the two lists will differ. ☐ Marketplace listings. Third-party seller pages using your content. ☐ Customer service. Chat transcripts, email templates, and phone scripts. ☐ Review responses. Replies to customer reviews are company statements. ☐ Trade materials. Sell sheets, distributor decks, conference booth graphics. ☐ Search terms purchased. Bidding on a disease term is itself a claim in some readings.

Flag any statement that the product treats, cures, mitigates, or prevents a disease or condition; any structure-function claim not substantiated; any comparison to a pharmaceutical; and any testimonial doing the work a claim cannot.

☐ Exposure framework — 21 U.S.C. § 331; 21 U.S.C. § 352; 21 U.S.C. § 355; labeling 21 U.S.C. § 343, 21 C.F.R. Part 101 ☐ ☐ Deceptive practices overlay — 15 U.S.C. § 45 principles and state analogues ☐ ☐ Findings written; removals documented with dates; a single approval owner appointed ☐

Tool 10 — Recall notification

Urgent — product recall notice

To: [distributors and retailers]

[Company] is recalling [product], lot codes [list], UPC [numbers], distributed between [dates].

Reason: [describe — cannabinoid content differs materially from label / contamination identified / packaging non-compliance]. [State the health risk plainly.]

Action required: Immediately remove all affected lots from sale and from display. Segregate and label them "HOLD — DO NOT SELL." Do not destroy any unit; retained units are required for testing. Identify any units sold to sub-distributors and notify them today. Report your on-hand quantity to [contact] by [date].

Consumer notification: [describe channels]. Consumers with affected product should [instruction]. Consumers with medical concerns should seek care and may contact [number].

Returns and credit: [terms].

Contact: [name], [phone], [email], available [hours].

☐ Framework — 21 C.F.R. Part 7 ☐ Hearing procedures if contested — 21 U.S.C. § 371; 21 C.F.R. Part 16 ☐ ☐ Seizure exposure understood — 21 U.S.C. § 334; penalties 21 U.S.C. § 333; hearing 21 U.S.C. § 335 ☐ ☐ Retained samples and all testing records preserved before anything is destroyed ☐ ☐ Product liability and recall carriers notified the same week ☐ ☐ Mock recall run annually; lot-to-customer identification achievable within hours ☐

Tool 11 — Diligence request list

Send this before valuing anything in this industry.

  1. All licenses, the plan under which each was issued, and the complete violation and corrective action history.
  2. Land or lot reports for every crop year, reconciled to actual production.
  3. Sampling records, laboratory reports, methods, chromatograms, and uncertainty statements for every lot in inventory and every lot sold in the past [period].
  4. Batch records for every conversion process, with reagents and starting materials identified.
  5. Finished-product certificates matched to lot codes on hand, with a physical spot check.
  6. Shipping records by state for [period], and the compliance analysis relied on for each destination.
  7. All label versions for every SKU, with effective dates.
  8. The complete claims audit described above, including archived and influencer content.
  9. All warning letters, state enforcement actions, seizures, and consumer complaints.
  10. All insurance policies in force, with exclusions highlighted, and all claims made.
  11. Trademark applications and registrations, including refusals and their grounds.
  12. All supply and distribution contracts, with hot-lot, conversion, channel, and change-in-law provisions identified.
  13. Payment processing history, including any termination and its stated reason.
  14. Any legal opinion obtained on the status of any cannabinoid sold.

☐ ⚠️ Price a definitional change as a real possibility within the holding period, and negotiate for it expressly. ☐ Regulatory context for the analysis — 21 U.S.C. § 321; 21 U.S.C. § 348; 21 U.S.C. § 350b; 21 U.S.C. § 360b ☐ ☐ Criminal exposure context — 21 U.S.C. § 841; 21 U.S.C. § 844; 21 U.S.C. § 881; scheduling 21 U.S.C. § 811, 21 U.S.C. § 812; registration 21 U.S.C. § 822, 21 U.S.C. § 823 ☐

Tool 12 — Insurance coverage questionnaire

Send to the broker in writing. Require written answers.

  1. Does the product liability policy cover ingestible products containing cannabinoids, including intoxicating cannabinoids? Identify the policy language.
  2. Does any controlled substance exclusion, cannabis exclusion, or unapproved-product exclusion apply? Quote each and explain the carrier's position.
  3. Are products the carrier considers unlawful under food and drug law excluded, and on what basis would that determination be made?
  4. Is there coverage for bodily injury arising from pediatric ingestion?
  5. Is recall coverage included, and at what limit?
  6. Is cargo covered if a load is seized in transit by law enforcement?
  7. Does crop insurance respond to a lot that exceeds the acceptable THC level, and under what cause of loss?
  8. Is there defense coverage for a regulatory investigation, and does it include criminal defense costs?
  9. Does the policy cover claims arising from advertising or claims made by influencers under contract?
  10. What notice is required, to whom, and within what period?

☐ ⚠️ Confirm every answer in writing before a claim exists. Carriers that answer generously in a sales conversation answer differently in a coverage letter. ☐ Civil exposure the coverage must reach — label accuracy class actions ☐ The federal statutes create no private right of action, so exposure is under state law ☐ aggregation posture per Shady Grove Orthopedic Associates, P.A. v. Allstate Insurance Co. ☐ preemption defenses limited by Buckman Co. v. Plaintiffs' Legal Committee, Wyeth v. Levine, and Mutual Pharmaceutical Co. v. Bartlett ☐

Tool 13 — Intake questions

  1. Is this raw plant material, an extract, a converted cannabinoid, or a finished product?
  2. Did any chemical conversion occur, and is it documented in the batch record?
  3. Which measurement governs at this stage — total THC or delta-9 concentration?
  4. Is the material traceable to a licensed producer and a reported lot?
  5. What does the certificate say, and can you produce the method, chromatogram, sampling record, and uncertainty?
  6. Is the product ingestible, topical, inhaled, or for animals?
  7. Has any disease claim been made anywhere, ever, including by an influencer?
  8. Which states does this product reach, and when was each last checked?
  9. What do the contracts say about a hot lot and about a change in the law?
  10. What insurance is in force, and what does it exclude?
  11. Has any load been stopped, seized, or refused delivery?
  12. Has any laboratory result ever been retested, and are the original results in the file?

☐ ⚠️ Questions 2 and 3 determine the answer to almost everything else. Ask them first, and require documents. ☐ Criminal posture if a seizure has occurred — knowledge and intent development per Ruan v. United States ☐

Related Documents